PMC:7507645 / 5369-5699 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7507645","sourcedb":"PMC","sourceid":"7507645","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7507645","text":"Eligible patients were randomized 1:1:1 to receive subcutaneous injections of either fremanezumab quarterly (675 mg of fremanezumab at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg of fremanezumab at baseline and 225 mg at weeks 4 and 8), or placebo (matching placebo at baseline and at weeks 4 and 8) [16].","tracks":[{"project":"TEST0","denotations":[{"id":"32958075-228-234-1506673","span":{"begin":326,"end":328},"obj":"[\"29171818\"]"}],"attributes":[{"subj":"32958075-228-234-1506673","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"32958075-29171818-60560880","span":{"begin":326,"end":328},"obj":"29171818"}],"attributes":[{"subj":"32958075-29171818-60560880","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#bfec93","default":true},{"id":"2_test","color":"#ec93d9"}]}]}}